Protocol Ledger

NCT05897320 · Phase III · RECRUITING

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Interventional Phase III clinical trial protocol NCT05897320 sponsored by H. Lundbeck in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-08 Enrollment: 315 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05897320
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)315 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05897320
Protocol FieldVerified Registry Value
NCT IdentifierNCT05897320
Consolidated Lead SponsorH. Lundbeck
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment315 participants (ESTIMATED)
Registered Start Date2023-06-08
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI